Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Resistance to nondepolarizing neuromuscular blocking agents

S J Tschida1, K J Graupe, L L Hoey

  • 1College of Pharmacy, University of Minnesota, Minneapolis, USA.

Pharmacotherapy
|May 1, 1996
PubMed
Summary

Resistance to nondepolarizing neuromuscular blocking agents (NNMBAs) can occur in critically ill patients, leading to adverse outcomes and increased costs. Understanding the causes of NNMBAs resistance is crucial for effective patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time to patient discontinuation of antihypertensive drugs in different classes.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

In favor of Coumadin over generic warfarin.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same author

Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries.

The Journal of burn care & rehabilitation·1997
Same author

Comment: Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis.

The Annals of pharmacotherapy·1996
Same author

The impact of practice guidelines on prescribing patterns of nondepolarizing neuromuscular blocking agents.

Pharmacotherapy·1996
Same author

QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature.

Pharmacotherapy·1996

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Anesthesiology

Background:

  • Nondepolarizing neuromuscular blocking agents (NNMBAs) are used for paralysis in critical care.
  • Resistance to NNMBAs has been reported in surgical and critical care settings.
  • Prolonged paralysis therapy in critically ill patients may be associated with NNMBAs resistance.

Purpose of the Study:

  • To review the phenomenon of NNMBAs resistance in critically ill patients.
  • To discuss potential adverse outcomes and pharmacoeconomic implications of NNMBAs resistance.
  • To explore potential pharmacodynamic and pharmacokinetic etiologies of NNMBAs resistance.

Main Methods:

  • Literature review of case reports and studies on NNMBAs resistance.
  • Analysis of potential contributing factors to resistance, including disease states and drug interactions.

Related Experiment Videos

  • Discussion of physiological alterations affecting drug response.

    • Main Results:

    • NNMBAs resistance can lead to inadequate ventilation and patient movement suppression.
    • Resistance may increase the risk of dose-dependent cardiovascular adverse effects.
    • Significant pharmacoeconomic burden associated with treating resistant patients.

    Conclusions:

    • The exact causes of NNMBAs resistance are not fully understood.
    • Pharmacodynamic alterations (e.g., acetylcholine receptor changes) and pharmacokinetic changes (e.g., altered clearance) may contribute to resistance.
    • Further research is needed to elucidate the mechanisms and optimize management strategies for NNMBAs resistance.